Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03023722 |
| Title | Phase II Anetumab Ravtansine as 2nd Line Treatment for Pancreatic Cancer |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Howard Hochster |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Yale Cancer Center | New Haven | Connecticut | 06510 | United States | Details | |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901-2163 | United States | Details | |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | United States | Details |